The longer-term picture is timing-dependent, since started near menopause it appears cognitively safe and may track with lower dementia risk, and the FDA removed the boxed warning, including the probable-dementia language, in 2026
Low in sugar, sweetened with Stevia!
(2) The peptide has been suggested to exhibit action similar to Epithalamin via various modes
Not interchangeable with FDA-approved GHRH analogs such as Tesamorelin (Egrifta)
Novo Nordisk spokesperson Allison Scheider says the company takes all reports about new side effects "very seriously," but added that this class of drugs has been used for more than 15 years
The slowed gastric emptying and altered motility patterns associated with GLP-1 therapy often manifest as bloating, abdominal distention, and early satiety